Vivitra 150mg Injection is a clinically established pharmaceutical preparation containing TRASTUZUMAB as its primary active ingredient. It falls under the Oncology therapeutic class and is widely prescribed for the management of associated medical conditions. The medicine exerts its action through a well-defined pharmacological mechanism, targeting specific receptors, enzymes, or biological pathways to produce the desired clinical effect. Manufactured by ZYDUS CADILA, Vivitra 150mg Injection is available in Injection form. This medicine is classified under the Anti Cancer general category and the Oncology speciality domain, reflecting its use within this therapeutic area. Patients should note that dosage and treatment duration must be individualized based on the patient's clinical condition, age, weight, organ function, and concurrent medications.

• Primary Indication: Management and treatment of conditions in the Oncology therapeutic domain as diagnosed and confirmed by a qualified specialist. • Combination Therapy: May be used as part of a multi-drug regimen to achieve synergistic therapeutic effects. • Monotherapy: Can be prescribed as a standalone agent where single-drug therapy is appropriate. • Maintenance Therapy: Used for long-term disease control and prevention of relapse. • Second-Line Therapy: Indicated in patients who have not responded adequately to first-line treatments. • Geriatric Use: Suitable for elderly patients with dose adjustments based on renal, hepatic, and cardiovascular status under close monitoring.

Vivitra 150mg Injection containing TRASTUZUMAB exerts its therapeutic effects through a well-defined pharmacological mechanism relevant to oncology conditions. The active ingredient interacts with specific molecular targets to modulate biological pathways and produce the desired clinical effect. Therapeutically, Vivitra 150mg Injection is classified under the Anti Cancer category and the Oncology speciality domain. Regular therapeutic monitoring is recommended to ensure optimal drug levels and evaluate treatment response.

• Always inform your doctor about every medicine you are currently taking before starting Vivitra 150mg Injection. • CYP450 Enzyme Interactions: Medicines that inhibit or induce CYP450 enzymes may significantly increase or decrease blood levels of TRASTUZUMAB. • Anticoagulants: Concurrent use may alter anticoagulant effect — monitor INR frequently. • Nephrotoxic or Hepatotoxic Agents: Avoid concurrent use unless supervised by a specialist with regular monitoring.

Vivitra 150mg Injection is a prescription-only medicine (Schedule H / H1 or equivalent) and must not be purchased or used without a valid prescription from a licensed medical practitioner. Storage: Store at 2-8°C. Do NOT freeze. Disposal: Do not flush unused medicines or dispose in household waste. Return unused or expired medicines to a licensed pharmacy. Regulatory Information: Manufactured by ZYDUS CADILA and complies with applicable drug regulatory standards. Pharmacovigilance: Report any unexpected, severe, or serious adverse effects to your doctor and to CDSCO in India through the online ADR reporting system.